Trial Profile

The impact of continuous terlipressin infusion on muscle, nutrition, ascites and inflammation in end-stage liver disease

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 07 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Terlipressin (Primary)
Indications Hepatorenal syndrome; Liver cirrhosis
Focus Pharmacodynamics; Therapeutic Use

Most Recent Events

24 Jun 2023 Results (n=23; till date) assessing muscle function and muscle mass in a sick cohort of cirrhotics for whom muscle function tends to steadily decline through week 12 presented at the European Association for the Study of the Liver Congress 2023
01 Aug 2019 Status changed from not yet recruiting to recruiting.
01 Jul 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com